Pharma & Biotech Events & Conferences
Refine Search
Pharmaceutical
Positive results from the Phase IV AUGUSTUS trial evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session 2019 in New Orleans. 18 March 2019
Biotechnology
Lyon-based biotech firm Erytech Pharma is to present new research at the European Red Cell Research Society (ERCS) in Switzerland. 11 March 2019
Biosimilars
At the JP Morgan Healthcare Conference in San Francisco, South Korea’s Celltrion outlined details of its business plan for 2019, confirming the firm’s main focus will be on the development of a subcutaneous form of CT-P13, a biosimilar version of the immunological therapy infliximab. 10 January 2019
Biotechnology
AstraZeneca and its global biologics research and development arm MedImmune, have presented overall survival (OS) and progression-free survival (PFS) data from the Phase III MYSTIC trial at the European Society for Medical Oncology (ESMO) Immuno-Oncology 2018 Congress in Geneva, Switzerland. 14 December 2018
Biotechnology
Swedish Orphan Biovitrum and Novimmune have presented positive data from a pivotal Phase II/III study of Gamifant (emapalumab-lzsg) at the annual meeting of the American Society of Hematology. 5 December 2018
Pharmaceutical
Janssen Pharmaceutical, the pharma business of US healthcare company Johnson & Johnson, has announced positive Phase III data for Darzalex (daratumumab) at the annual meeting of the American Society of Hematology. 5 December 2018
Biotechnology
Swiss pharma giant Roche has presented data from the largest pivotal study to date in children with hemophilia A at the American Society of Hematology Annual Meeting. 4 December 2018
Biotechnology
BeiGene clinical data from the pivotal Phase II trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL), at the Annual Meeting of the American Society of Hematology (ASH) yesterday. 4 December 2018
Pharmaceutical
Daiichi Sankyo yesterday announced positive comprehensive analyses of overall survival from the pivotal QuANTUM-R Phase III study of single agent quizartinib compared to salvage chemotherapy in patients with FLT3-ITD acute myeloid leukemia (AML). 4 December 2018
Pharmaceutical
Basel, Switzerland-based Roche has announced new Phase III data for Venclyxto (venetoclax) at the annual meeting of the American Society of Hematology. 4 December 2018
Pharmaceutical
AstraZeneca and its hematology subsidiary Acerta Pharma have presented new, long-term follow-up results for Calquence (acalabrutinib) at the annual meeting of the American Society of Hematology. 4 December 2018
Pharmaceutical
Takeda Pharmaceutical has presented positive results from the Phase III TOURMALINE-MM3 study of Ninlaro (ixazomib) at the annual meeting of the American Society of Hematology (ASH). 3 December 2018
Biotechnology
US biotech firm Seattle Genetics’ shares gained 2.75% to $64.3-in pre-market trading today, after it highlighted data from the ECHELON-1 Phase III clinical trial evaluating Adcetris (brentuximab vedotin) at the ASH meeting. 3 December 2018
Biotechnology
China’s BeiGene on Saturday announced clinical data from two ongoing trials of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, in patients with mantle cell lymphoma (MCL), at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place December 1-4, 2018 in San Diego, USA. 3 December 2018
Biotechnology
Gilead Sciences company Kite Pharma released positive two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. 3 December 2018
Biotechnology
In a Phase III clinical trial, presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, USA, on the opening day, December 1, the experimental drug luspatercept significantly reduced the need for blood transfusions in patients with the inherited blood disorder beta thalassemia. 2 December 2018
Pharmaceutical
A look at what's coming up at one of pharma's most important conferences. 30 November 2018
Biotechnology
Switzerland’s Roivant Sciences has launched a new biotech startup, in collaboration with the Cincinnati Children's Hospital Medical Center, called Aruvant Sciences. 27 November 2018
Generics
The 2nd Value Added Medicines conference, which took place in Brussels, Belgium, yesterday, gathered a wide range of experts in the healthcare community to raise awareness, informed debate with the mutual intention to present solutions for maximizing the benefits of and encouraging the development of continuous innovation. 22 November 2018
Pharmaceutical
AbbVie has released new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, Mavyret (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis. 14 November 2018
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze